LPA1 inhibition induces metastatic dormancy in mouse models of breast cancer

A lysophosphatidic acid receptor 1 (LPAR1) inhibitor, known as Debio-0719, suppresses the development of metastases in mice by inducing cancer cell dormancy, according to a study published August 21 in the Journal of the National Cancer Institute.

Metastasis is a main contributor to mortality in cancer patients. Patients with "triple negative" breast cancer (tumor cells that are hormone receptor negative and express normal levels of the HER2 oncogene) are known to be at high risk for metastatic progression.

In addition, breast and are known for having variable but possibly long periods of dormancy, where the disease is silent. Factors inducing or breaking a dormant state are poorly understood, but extending dormancy is considered a therapeutic goal.

To determine the effects of LPA1 inhibition on metastatic dormancy, Jean-Claude A. Marshall, MSc., Ph.D. of the Women's Cancers Section, Laboratory of Molecular Pharmacology, Center for Cancer Research, NCI, and colleagues analyzed primary , distant metastases and their molecular characteristics in two model systems of aggressive "triple negative" , the murine 4T1 mammary carcinoma model and human MDA-MB-231 human model. Debio-0719 or shRNA knockdown of LPA1 significantly inhibited metastasis formation without affecting primary tumor size. found in distant organs, such as the lungs and liver of Debio-0719 treated mice, had ceased proliferation and exhibited other molecular hallmarks of dormancy. LPA1 inhibition represents one of the first compounds to induce dormancy in metastatic sites in triple negative breast cancer.

The authors point out that LPA1 inhibition had no effect on the growth of the primary tumors in either model system. As such, it would not normally be considered further for drug development. Their data suggest that alternative drug development approaches may identify compounds with novel activities, such as metastatic dormancy.

The authors point out that their study did not determine the duration of tumor dormancy, and that Debio-0719 and other LPA1 inhibitors should be tested in additional model systems. However, they conclude: "With such inhibitors in hand, the interaction of dormancy pathways and standard of care therapeutics, radiation therapy, patient stress, and other important factors can be determined to develop a deeper picture of potential preventative and therapeutic scenarios."

add to favorites email to friend print save as pdf

Related Stories

Drug shows promise for triple-negative breast cancer

Jul 03, 2012

(Medical Xpress) -- A promising new therapy for hard-to-treat triple-negative breast cancer has been reported in the journal Breast Cancer Research by a team at the Tulane University School of Medicine, led by ...

Probing the mechanism of ADAM28-mediated cancer metastasis

Jun 08, 2012

ADAM28, a metalloproteinase belonging to the ADAM gene family, cleaves the von Willebrand factor (VWF) and inhibits VWF-mediated cancer cell apoptosis, thereby enhancing lung metastases, so inhibiting its expression gives ...

Tracking breast cancer cells on the move

Jun 14, 2012

Breast cancer cells frequently move from their primary site and invade bone, decreasing a patient's chance of survival. This process of metastasis is complex, and factors both within the breast cancer cells and within the ...

Recommended for you

Blood biomarker may detect lung cancer

16 hours ago

A new study shows that patients with stage I to stage III non-small cell lung cancer have different metabolite profiles in their blood than those of patients who are at risk but do not have lung cancer. The study abstract ...

ACG: Recent increase in incidence of young-onset CRC

Oct 20, 2014

(HealthDay)—The incidence of young-onset colorectal cancer (CRC) is increasing, and the disease is more aggressive pathologically. These findings are being presented at the annual meeting of the American ...

User comments